Pathological specimens may also inform adjuvant therapy choice by providing insight into each patient’s specific tumor adaptations, mechanisms of resistance, and biomarkers, such as postsurgical tumor mutational burden and IFN-γ score [239]. The gene discussed is IFNG; the disease is neoplasm.